Evotec SE (NASDAQ:EVO - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $4.30, but opened at $4.10. Evotec shares last traded at $4.09, with a volume of 94,091 shares.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.
Get Our Latest Stock Analysis on EVO
Evotec Stock Down 3.2%
The business's fifty day moving average price is $3.61 and its 200-day moving average price is $4.17. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. DCF Advisers LLC raised its position in Evotec by 227.0% in the first quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after acquiring an additional 521,708 shares during the period. ABC Arbitrage SA bought a new stake in Evotec in the first quarter worth about $260,000. Lighthouse Investment Partners LLC bought a new stake in Evotec in the fourth quarter worth about $166,000. CSS LLC IL bought a new stake in Evotec in the fourth quarter worth about $50,000. Finally, Bank of America Corp DE raised its position in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
